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Abstract 
BIRC7, also known as livin, is a member of the 
Inhibitor of Apoptosis Protein (IAP) family and is 
linked to the prevention of cell death induced by 
apoptosis, by directly or indirectly preventing 
caspase activity. In general, as most IAPs, BIRC7 
expression is not detectable in normal differentiated 
adult tissues, with the exception of placenta, spleen, 
lymph nodes and developing embryonic tissues. On 
the other hand, BIRC7 overexpression has been 
reported in a variety of tumor types, in which it is 
associated to malignancy and chemoresistance. 
Currently, there are some unanswered questions 
about BIRC7, including its interaction with caspases, 
a potential paradoxical role in the apoptotic process, 
and specific functions/affinities of the BIRC7α and 
BIRC7β splice variants. Moreover, several studies 
have demonstrated the value of BIRC7 as a 
therapeutic target in a number of cancer types. This 
review mainly focuses on the role of BIRC7 in 
cancer cell biology and its clinical significance, 
demonstrating aspects of its DNA/RNA and protein, 
as well as its relevance in cancer diagnosis and 
prognosis. 
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The BIRC7 gene is about 4.6 Kb (start: 63235883 bp 
and end: 63240507 bp; orientation: plus strand). 
There are two transcript variants deposited in the 
NCBI database 
(https://www.ncbi.nlm.nih.gov/gene). The transcript 
variant 1 (cDNA: 1334 bp) encodes the longer 
isoform (alpha; BIRC7α) (298 aa). The transcript 
variant 2 (cDNA: 1280 bp) presents an alternate in-
frame splice site and encodes the shorter isoform 
(beta; BIRC7β) (280 aa). Isoform α blocks 
staurosporine-induced apoptosis and augments 
killing by natural killer (NK) cells, while isoform β 
blocks etoposide-induced apoptosis and protects 
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against NK cell. There is an additional transcript 
variant reported in Ensembl 
(http://www.ensembl.org/), which contains a cDNA 
of 593 bp, and generates a protein with 193 aa. 
Protein 
Description 
The IAPs (Inhibitors of Apoptosis Proteins) are a 
family of proteins recognized, predominantly, for 
their role in preventing apoptotic cell death by 
directly or indirectly hindering caspase activity. 
Nevertheless, these proteins are further involved in 
other signaling pathways associated to cell survival, 
cell cycle and cell migration (Gyrd-Hansen & Meier, 
2010; Owens et al., 2013; Plati, Bucur  Khosravi-Far, 
2011). The presence of, at least, one BIR domain 
(baculovirus IAP repeat), a conserved sequence of 
about 80 amino acid residues with Zn+2 in the center, 
which mediates the protein-protein interactions with 
caspases being essential for their anti-apoptotic 
activity, is the structural distinctive of the family 
(Budhidarmo & Day, 2015; Deveraux & Reed, 1999; 
Lopez; Meier, 2010). Eight IAPs have been 
identified within the human proteome - NAIP 
(BIRC1), cIAP1 ( BIRC2), cIAP2 ( BIRC3), XIAP 
(BIRC4), survivin ( BIRC5), Apollon/Bruce ( 
BIRC6), livin/ML-IAP (BIRC7) e ILP-2 ( BIRC8), 
and these may present either one or three BIR 
domains arranged in their N-terminal portion  
 (Budhidarmo & Day, 2015; Deveraux & Reed, 
1999; Lopez  Meier, 2010).  
BIRC7 is a 39 kDa member of the IAP family, 
structured with a single BIR domain, added with a 
RING domain on the C-terminus portion, as firstly 
described by Vucic and colleagues in the year 2000 
(Figure 1). Its BIR domain is globularly assembled, 
with four α-helixes and a three-strand anti-parallel β-
sheet (Hinds et al., 1999). In turn, the RING-type 
zinc-finger domain, alike in other RING-bearing 
IAPs, has ubiquitin-ligase (E3) activity and, thus, is 
associated with the ubiquitination functionality; 
however further studies have demonstrated 
additional and yet unclear roles in addressing 
apoptotic activity (Ma et al., 2006).  
A distinctive feature of this protein is that, unlike any 
other IAP, following a strong apoptotic incitement, 
BIRC7 is cleaved by CASP3 and CASP7 (caspases-
3 and -7) at Asp52 to give a truncated form, which, 
paradoxically, promotes cell death (Nachmias et al., 
2003). 
 
Figure 1. Structure of BIRC7 and its variants.  BIRC7 (also known as livin) protein structure has 39 kDa and is composed of a 
single BIR domain containing approximately 70 amino acids (aa) and zinc binding residues. The protein nucleus is generally 
connected with a conserved cysteine and is rich in histidine, and is connected to its anti-apoptotic activity. Additionally, the RING 
domain, which gene covers 4.6 kb in chromosome 20, band q13, is composed by six introns and seven exons. Structurally, 
BIRC7-BIR forms a globular architecture preserved by four α-helices and an anti-parallel sheet of three filaments, as well as 
residues that form the hydrophobic nucleus. The RING domain is usually defined by seven cysteines and a histidine that can 
coordinate two zinc atoms in its carboxy terminal. BIRC7 has two similar variants, α and β, differing by 18 amino acids located 
between the BIR and RING domains, present only in the isoform α. Both isoforms have shown biological relevance to cancer. 
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By such trait, rather than merely an apoptosis 
inhibitor, BIRC7 may actually be allowed to a 
broader title, one of a cell death regulator. 
Furthermore, through alternative splicing of the 
mRNA, BIRC7 has two splice variants, BIRC7α and 
BIRC7β, which have different subcellular 
distribution and distinct anti-apoptosis properties. 
Still, the BIR and RING domains are identical in 
both isoforms, and their only structural difference is 
assumed by the 18 amino acids present between 
these domains in the α isoform, allowing the 
formation of an α-helix linker (Ashhab et al., 2001; 
Li et al., 2013a).  
For BIRC7, there are currently a number of 
unanswered questions concerning the protein 
interaction with caspases, the paradoxical activities 
it can undertake during apoptosis and, also, on 
specific functions and affinities of the α and β 
variants. Still, taken the range of activities and 
regulatory motifs of the protein, BIRC7 has been 
regarded as an interesting target for cancer therapy. 
As this IAP displays such unique pro- and anti-
apoptotic properties, a treatment strategy could 
involve the promotion of BIRC7 cleavage, directing 
accumulation of the truncated protein, in an attempt 
to tip the scale towards the pro-apoptotic effect, to 
counteract apoptosis resistance promoted by IAPs 
and other disrupted signaling pathways present in 
cancer cells (Wang et al., 2008). Other therapeutic 
opportunities include targeting BIRC7 at the 
transcriptional level using antisense 
oligonucleotides, thus, reducing the expression 
levels of the protein. Interestingly, antisense IAP 
therapy is also under clinical testing for XIAP and 
BIRC5, with promising candidates (Xia et al., 2002; 
Hu et al., 2003). 
Expression 
Much like most IAPs, BIRC7 has low or even no 
detectable expression in normal differentiated adult 
tissues, but is present in high levels in placenta, 
spleen, lymph nodes, developing/embryonic tissues 
and in a variety of tumor types (Li et al., 2013a). In 
fact, BIRC7 overexpression has been recorded in 
numerous cancers, however, it is best linked to the 
malignancy in which it was preferentially 
overexpressed when it was originally detected - 
melanoma -, justifying the attributed label of ML-
IAP (melanoma inhibitor of apoptosis proteins) 
(Vucic et al., 2000). BIRC7 protein levels have been 
found upregulated in primary tumors as well as in 
various melanoma cell lines, whereas it was only 
detectable in negligible amounts in melanocytes or 
nevi. Still, in melanoma, high levels of BIRC7 have 
been associated to chemoresistance and poor 
prognosis, while intermediate levels (but not 
necessarily the total lack of BIRC7 expression) were 
related to a better prognosis - possibly due to the pro-
death activity of the truncated forms of the protein 
(Gong et al., 2005; Lazar et al., 2012).  
Gastric, prostate, bladder, breast, renal and liver 
carcinomas, along with neuroblastoma, leukemia, 
and lymphomas, as well as non-small cell lung, 
cervical, liver and pancreatic cancers have all been 
related to BIRC7 upregulation (Gazzaniga et al., 
2003; Tanabe et al., 2004; Hariu et al., 2005; Kim et 
al., 2005; Wagener et al., 2007; Augello et al., 2009; 
Yuan et al., 2009; Wang et al., 2010; El-Mesallamy 
et al., 2011; Lazar et al., 2012). In neuroblastoma, 
bladder and gastric cancers, higher levels of BIRC7 
expression could be pondered as a risk factor, once 
isoform α, but not β, was predominant in bladder 
cancerous tissue but neither isoform occurred in the 
healthy tissue (Gazzaniga et al., 2003). In gastric 
cancer, nearly half of the assessed patients expressed 
both isoforms in their tumorous tissue, however 
benign gastric lesions showed no detectable BIRC7 
expression (Wang et al., 2010).  
Moreover, Ashhab and colleagues (2001) assessed 
mRNA transcripts of BIRC7α and BIRC7β in a 
panel of human tumor cell lines and upregulation of 
both isoforms was detected in melanoma, colon, and 
prostate carcinoma cells. Nevertheless, when 
measured in normal fetal and adult tissues, different 
expression levels for each isoform suggests a 
specific pattern of splicing and expression related to 
histology. Notable levels of BIRC7β were found 
mainly in fetal kidney, spleen, and heart, whereas no 
BIRC7α was detected in fetal tissues. Adult tissues, 
such as heart, placenta, lung, spleen and ovary 
showed upregulation of both isoforms, while only 
the α isoform was detected in brain, skeletal muscle 
and lymphocytes (Ashhab et al., 2001). 
Localisation 
BIRC7 can be found both in the nucleus and in the 
cytoplasm, and the localization of this IAP has been 
compared to that of BIRC5 (Kasof  Gomes, 2001). 
Nevertheless, full-length forms of both BIRC7 
variants are present exclusively in the cytoplasm, 
while a peri-nuclear distribution is seen for the pro-
apoptotic truncated forms of BIRC7 (t-livin), with 
prominent accumulation in the Golgi apparatus 
(Nachmias et al., 2007a). In fact, subcellular 
localization has been known to regulate the different 
roles of IAPs in the apoptosis process (Ambrosini et 
al., 1998). In this context, Nachmias and colleagues 
(2007) have demonstrated that the N-terminal region 
of t-livin directs the peri-nuclear distribution and this 
arrangement is essential, but not enough, to give t-
livin its pro-apoptotic activity. The RING domain, 
whose purposes have been afflicted with much 
ambiguity among distinct IAPs, then fulfills the 
operative role in the properly localized t-livin's pro-
apoptotic functions.  
Point mutations to the RING domain resulted in 
proper peri-nuclear distribution and further Golgi 
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localization, but abrogated the pro-apoptotic effect 
of t-livin. However, RING-mutated full-length 
BIRC7 was found in both nucleus and cytoplasm, 
suggesting that RING domain, opposite to what was 
observed for the truncated forms, may affect the sub-
cellular localization of full-length BIRC7 (Nachmias 
et al., 2007a). Moreover, while the occurrence of 
intact full-length BIRC7 in the cytoplasm directly 
correlates with resistance to apoptosis, the presence 
of t-livin in the nucleus is associated with increased 
cellular apoptosis. 
Function 
Most IAPs are thought to directly interact with 
caspases and block their activity (Kasof & Gomes, 
2001), and the integrity of the BIR domain is 
necessary to achieve this effect. In fact, BIRC7 has 
been initially proposed to bind and inhibit CASP9, 
but not CASP1, CASP2, CASP3, CASP6, CASP7 or 
CASP8 (Vucic et al., 2000; Vucic et al., 2002). 
However, subsequent work carried out by the same 
group demonstrated that BIRC7 established a 
weaker interaction with caspases 3 and 9 when 
compared to that of XIAP (Vucic et al., 2005) 
(Figure 2). Moreover, three critical BIR residues 
were found responsible for BIRC7's lower caspase 
inhibition potency - Ser150, Gln167 and Glu168 - 
while XIAP's corresponding residues- Gly326, 
His343, and Leu344- rendered the latter IAP a 
stronger inhibitor. Once the critical residues were 
replaced for those of XIAP, the mutant BIRC7 
actually showed greater inhibition towards caspase 9 
than native XIAP (Vucic et al. 2005). Nevertheless, 
BIRC7 was demonstrated to bind with high affinity 
to the pivotal pro-apoptotic, IAP-antagonizer 
mitochondrial protein DIABLO (SMAC) through 
the BIR domain, while BIR-mutations were shown 
to abolish BIRC7-SMAC/DIABLO interaction (Ma 
et al., 2006). In this scenario, the anti-apoptotic 
function played by BIRC7 is essentially revealed 
through the sequestration of SMAC/DIABLO, thus 
abrogating the anti-IAP effect exerted by such 
protein (Chai et al., 2000; Liu et al., 2007). 
Furthermore, Ma and colleagues (2006) showed that 
BIRC7, in fact, resorts to the E3 ubiquitin ligase 
function of the RING domain to target 
SMAC/DIABLO for degradation through the 
ubiquitin-proteasome pathway.  
BIRC7 has prompted apoptosis blockage induced by 
a number of death receptors, such as FAS, 
TNFRSF1A (TNFR1), TNFRSF10A (DR4) and 
TNFRSF10B (DR5) (Vucic et al., 2000), and has 
been associated to other proteins that are within the 
apoptotic pathway, thus inducing further indirect 
caspase inhibition. Similar to XIAP, the ability of 
BIRC7 to activate MAPK8 (JNK1), a protective 
pathway against apoptosis induced by TNF (TNF-
&alpha); and interleukin, was verified by the 
MAP3K7 / TAB1 (TAK1/TAB1) signaling cascade 
(Sanna et al., 2002; Chen et al., 2010). Moreover, 
BIRC7 may play a role in the WNT/ CTNNB1 
(Wnt/β-catenin) signaling pathway, a key 
component of gene activation with outcomes on 
tumor development through the activity of TCF (T-
cell factor) transcription factors (Uematsu et al., 
2003). Indeed, Yuan and collaborators (2007) 
confirmed BIRC7 to be a target of the β-catenin/TCF 
complex, suggesting their transcriptional regulation 
by upon BIRC7 (Yuan et al., 2007). Recent studies 
have also demonstrated a role for BIRC7 in 
regulating the epithelial-mesenchymal transition in 
colorectal cancer cells, favoring metastasis by the 
activation of the p38/ GSK3B pathway (Han et al., 
2017).  
BIRC7 overexpression has been also associated with 
tumor aggressiveness, chemoresistance and reduced 
sensitivity to radiation, while silencing of BIRC7 has 
been shown to lessen such features, both in vitro and 
in vivo. When SMMC-7721 cells were transfected 
with BIRC7 siRNA, mRNA and protein levels of 
both splice variants, BIRC7α and β, were greatly 
downregulated. Moreover, transfected cells 
displayed G1-arrest and a diminished S-phase cell 
count, reduced invasiveness, and re-established a 
response to apoptotic stimuli (Liu et al., 2010). 
BIRC7-silenced SCG-7901 cells, in turn, regained 
sensitivity to cytotoxic chemotherapy drugs, such as 
5-fluorouracil (5-FU) and cisplatin (Wang et al., 
2010). In xenograft models, HCT116 tumors treated 
with BIRC7 siRNA presented reduced volume in a 
dose-dependent fashion, while mice maintained 
healthy body weight and no signs of toxicity (Oh et 
al., 2011). Animal models were also used to 
demonstrate the differential effects of BIRC7 
isoforms in tumorigenesis. BIRC7α was shown to 
promote tumor progression, whereas those 
expressing BIRC7β inhibited tumor growth due to 
high degrees of cleavage, mediated by natural killer 
(NK) cells activity, of this variant into t-livin, which 
has a pro-apoptotic effect. Nevertheless, the 
expression of a mutated BIRC7β with lowered 
inclination to undergo cleavage restored a positive 
effect of tumor growth (Abd-Elrahman et al., 2009). 
In turn, it was also established that, while BIRC7α 
enhanced killing by NK cells, the β variant took on a 
modest protective effect against apoptosis induced 
by NK cells, however, in Jurkat cells, this action 
occurred alongside a concurrent inhibitory trigger, 
and not self-sufficiently. Nevertheless, when both 
isoforms were detected in melanoma cells, a low 
killing rate was observed (Nachimas et al., 2007b).  
The paradoxical pro-apoptotic effects of BIRC7, 
although baring intact BIR domains, are exerted by 
the truncated forms of both variants; still, t-livin β 
was found to give a stronger, however less stable, 
pro-apoptotic effect than t-livin α. t-Livin occurs 
around the cell nucleus, although not sturdily bound 
to that, and accumulates in the Golgi apparatus. 
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Resorting to mutagenesis and co-localization 
studies, Nachmias and colleagues further 
demonstrated that an intact RING domain and 
merely the first N-terminal glycine (G53) residue 
were sufficiently responsible for t-livin's localization 
to Golgi apparatus and also for its pro-apoptotic 
function, while deletion of either of these regions 
resulted in restoration of anti-apoptotic effect 
(Nachimas et al., 2007a). Additionally, t-livin has 
also been termed a flexible inducer of cell death once 
Shiloach and colleagues (2014) recognized its 
capacity of inciting necrosis, like in 293T cells, or 
apoptosis, like in A549 and MelA1, and such 
distinction may be possibly linked to TP53 status. 
Moreover, once the BIR domain was deleted from t-
livin, the prior necrotic effect observed in 293T cells 
was replaced by an apoptotic effect, regardless of its 
inactive TP53. Both effects, apoptosis and necrosis, 
were linked to activation of JNK pathway.  
However, once the BIR domain was deleted from t- 
 
livin, 293T cells failed to express JNK, suggesting a 
role for BIR in activation of this pathway. In MelA1 
cells, when these were treated with a pan-caspase 
inhibitor, t-livin-induced cell death was only 
partially abrogated, implying an aptitude of t-livin to 
induce cell death in situations where the apoptotic 
process is compromised (Shiloach et al., 2014). 
Homology 
BIRC7 has a high homology among different species 
(Table 1).  
% Identity for: Homo 
sapiens BIRC7 
Symbol Protein DNA 
vs. X. tropicalis birc7  55.4  58.2  
vs. D. rerio birc7  60.3  62.7  
vs. G. gallus BIRC7  55.4  58.2  
vs. D. rerio birc7  59.1  65.0  
vs. G. gallus BIRC7  60.3  62.7  
vs. X. tropicalis birc7  59.1  65.0  
Table 1.  Comparative identity of human BIRC7 with other 
species (Source: http://www.ncbi.nlm.nih.gov/homologene) 
 
 
Figure 2. Suggested mechanisms of action of BIRC7 on apoptosis regulation.  BIRC7 (livin) acts on cytoplasm and nucleus and 
is involved different cellular functions: cell survival, epithelial mesenchymal transition and up-regulation of pro-survival genes. In 
cytoplasm, BIRC7 modulates apoptosis pathway by indirectly regulating caspases 3 and 7. BIRC7 may block SMAC/DIABLO, a 
factor released by mitochondria, which subsequently inhibit the BIRC4 (XIAP). Also, BIRC7 induces the phosphorylation of P38, 
inhibiting GSK3B. It also induces the phosphorylation of JNK, mediating the translocation of C-JUN to the nucleus that induces 
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Somatic 
Recurrent mutations in the BIRC7 gene are rare. 
Among the 48,467 unique samples reported in 
COSMIC (Catalogue of Somatic Mutations in 
Cancer; 
http://cancer.sanger.ac.uk/cancergenome/projects/c
osmic), only 99 presented BIRC7 mutations (71 
missense substitutions, 26 synonymous 
substitutions, 2 nonsense substitutions, and 1 
frameshift insertion). Similar findings are reported in 
cBioPortal (http://www.cbioportal.org), in which, 
among the 10,967 cancer samples accessed, somatic 
mutations in BIRC7 were shown in merely 0.5% of 
the tested samples (corresponding to 59 mutations, 
of which 54 are missense substitutions, 4 truncated 
genes, and 1 other mutation). BIRC7 gene has been 
localized to the long arm of chromosome 20 on 
20q13.3, a region frequently amplified in melanomas 
and other malignancies (Vucic et al., 2000; Ibrahim 
et al., 2014; Choi et al., 2019); 
Implicated in 
Ampullary carcinoma 
In ampullary carcinoma, BIRC7 was detected in 
46.5% of cases, in which its expression was found 
predominantly in the cytoplasm, and only in 2.8% in 
the nucleus. High BIRC7 expression positively 
correlated with cell differentiation, tumor-node-
metastasis (TNM) staging, and lymph node 
metastasis. BIRC7 expression correlated negatively 
with caspase 3 levels and positively with Ki-67 
levels, demonstratinsg a decrease in apoptosis rate 
and an increase in cell proliferation in this cancer 
type. In addition, survival of patients with high 
BIRC7 expression was shorter compared with that of 
patients with low BIRC7 expression (Xue et al., 
2013). 
Breast cancer 
The investigation of BIRC7 gene expression in 8 
breast cancer cell lines revealed that this gene was 
expressed in all cells assessed. At least 6 out of the 8 
breast cancer cell lines (BT549, MDA-MB-435, 
MDA-MB-231, MDA-MB-468, MCF-7, SK-BR-3 
and ZR-75-30) showed relatively increased BIRC7 
mRNA and protein expression compared to the non-
malignant breast cell line, HBL100. Moreover, 
BIRC7 expression was found in higher levels in 
invasive breast cancer cells, when compared to non-
invasive ones (Fan et al., 2013, Crnkovic-Mertens et 
al., 2010).  
Clinicopathological studies revealed that the 
expression levels of BIRC7 in breast cancer tissues 
(62%) are higher than that of adjacent (35%) and 
normal breast tissues (25%). Still, the expression of 
BIRC7 in breast cancer is not closely related to age, 
menopause status, histological grade, ESR1 
(estrogen receptor), or PGR (progesterone receptor) 
status. However, expression of BIRC7 is higher in 
breast cancers classified under histological grade III 
when compared to grades I and II (88.9% vs. 46.9%). 
Similarly, the positive expression rate of BIRC7 in 
TNM in breast cancer stages III and IV (87.5%) was 
higher than in other stages (50%). In breast cancer 
cells, BIRC7 gene silencing induced G0/G1 cell 
cycle arrest. BIRC7 was highly expressed in high-
invasive breast cancer cells and promoted breast 
cancer cell migration and invasion via the activation 
of AKT signaling and induction of epithelial-
mesenchymal transition (EMT) in vitro and in vivo 
(Li et al., 2012).  
EMT is a key step in tumor progression via the 
induction of a highly invasive phenotype, and its 
molecular mechanisms have been extensively 
studied. The loss of epithelial markers such as CDH1 
(E-cadherin), and the gain of mesenchymal markers 
such as CDH2 (N-cadherin) and VIM (vimentin) are 
the hallmarks of EMT. Overexpression of BIRC7 
resulted in a similar loss of epithelial markers and a 
gain of mesenchymal markers, suggesting that 
BIRC7 was actively involved in the EMT process in 
breast cancer cells. These results suggested that 
BIRC7 participates of EMT by altering expression 
and activation of proteins involved in metastasis (Li 
et al., 2013b).  
Together, these findings indicate that BIRC7 
promoted the progression and metastasis of breast 
cancer through the regulation of EMT by activating 
the p38/GSK3β pathway. A deeper understanding of 
the role of BIRC7-induced EMT in breast cancer 
may provide effective targets for therapy, especially 
in triple-negative breast cancer (Han et al., 2017, Etti 
et al., 2017). 
Central nervous system cancer 
BIRC7 overexpression was reported in cerebral 
neoplasms, including neuroblastomas, 
glioblastomas, and tumors derived from neural crest 
cells. In most brain tumors, upregulation of BIRC7 
expression was associated with radio- and 
chemotherapeutics resistance (Dasgupta et al., 
2010).  
In neuroblastomas, 80% of cases presented high 
BIRC7 expression. Experimental findings indicate 
that BIRC7 may play a role in drug-resistance in 
neuroblastoma, particularly in aggressive and 
MYCN amplified tumors. These data strongly 
support that therapeutic targeting of BIRC7 to block 
its antiapoptotic effect could be an interesting 
strategy for the treatment of this disease (Dasgupta 
et al., 2010).  
In glioblastoma multiforme, the tumor hypoxia-
induced BIRC7 expression may represent a pathway 
for resistance to radio- and chemotherapeutics, since 
experimental studies showed that siRNA directed 
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against BIRC7 inhibited tumor growth (Hsieh et al., 
2014; Yuan et al., 2011). 
Cervical carcinoma 
Cervical cancer is one of the common gynecologic 
malignancies, and resistance to cisplatin is a concern 
in the clinical practice. In functional studies using 
the human cervical adenocarcinoma cell line, HeLa 
(which highly expresses BIRC7), inhibition of 
expression of BIRC7 by RNAi enhanced the activity 
of caspase 3, reduced BCL2 expression, and 
increased BAX, further inducing apoptosis and 
improving the effects of cisplatin (Yu  Wang, 2009). 
Colorectal cancer 
BIRC7 expression was detected in 54.1% of patients 
with colorectal cancer, specifically on the base of 
colorectal crypts in adenoma and throughout the 
epithelium in carcinoma, while such protein was not 
detected in normal colorectal mucosa (Xi et al., 
2011), (Wang et al., 2014). A high BIRC7 
expression rate was negatively associated to overall 
survival, but showed no correlation with age, gender, 
degrees of differentiation, and TNM staging in this 
malignancy (Xi et al., 2011; Myung et al, 2013).  
In primary tumors, BIRC7 expression was 
significantly increased compared with adjacent or 
distant normal mucosa, in which expression was 
independently related to survival outcomes in 
patients with rectal cancer (Ding et al., 2013). In 
addition, BIRC7 was related to pathological grade, 
extent of invasion and amount of lymph node 
metastasis, contributing to poor prognosis of mid-
distal rectal cancer following surgery (Su et al., 
2017).  
Overexpression of BIRC7 induced proliferation, 
migration, and invasion of cancer colorectal cells, 
which was reverted by BIRC7 depletion. Moreover, 
this overexpression promoted EMT, as evidenced by 
a decrease in E-cadherin expression and an increase 
in mesenchymal markers, including vimentin, 
SNAI2 (SLUG), and SNAI1 (SNAIL) (Ge et al., 
2016). Additionally, knockdown of BIRC7 
promoted cell cycle arrest by decreasing CCND1 36 
and CCND3 (cyclins D1 and D3), CDK4 and CDK6, 
and by inducing CDKN1B (p27) expression.  
Moreover, MAPK signaling cascades were 
significantly blocked by knockdown of BIRC7 
(Myung et al, 2013), while BIRC7 silencing using 
siRNA also decreased cell proliferation and 
clonogenicity and increased apoptosis rates (Zou et 
al., 2014).  
In colorectal cancer cell lines, BIRC7 expression 
was attributed to cisplatin resistance. BIRC7 mRNA 
levels was upregulated after cisplatin treatment in a 
dose- dependent manner.  
By contrast, knockdown of BIRC7 by siRNA 
rendered colon cancer cells more sensitive to 
cisplatin, reinforcing its involvement in 
chemoresistance (Ding et al., 2013). BIRC7 
knockdown also improved the sensitivity of 
colorectal cells to 5-FU (Liu et al., 2018). Colorectal 
cancer chemoresistance in HCT-8/V due to 
overexpression of this protein has also been 
attributed in response to vincristine (VCR), 
etoposide (VP-16), and 5-FU (Wang et al., 2010). 
Esophageal carcinoma 
BIRC7 expression was associated with tumor 
staging and progression in human esophageal 
carcinoma. Moreover, a positive correlation with 
VEGFA expression has also been demonstrated in 
these tumor types (Chen et al., 2008). 
Gastric cancer 
BIRC7 expression was found in 52.5% of gastric 
cancer samples, compared to 6.7% in that of adjacent 
normal gastric tissues (Liang et al., 2012). Similar 
results were described by Ou et al. (2014), who 
revealed that BIRC7 expression was elevated in 
tumors (64.1%) when compared to adjacent non-
cancer tissues (30.8%) obtained from patients with 
gastric cancer. Both studies found a positive 
correlation of BIRC7 expression with tumor 
differentiation and lymph node metastasis.  
Furthermore, Ou et al. (2014) demonstrated that 
BIRC7 depletion inhibited cell proliferation and 
invasion and induced apoptosis - showed by 
decreased expression of p38 MAPK, VEGF, and 
MMP2 and increased expression of caspase 3 in 
vitro. This feature also induced cell cycle arrest, with 
a decrease of cyclin D1 and CDK4 and CDK6, and 
an increase in expression of CDKN1A (p21) and 
CDKN1B (p27) (Chung et al., 2013). Comparably, 
in vivo assessments proved tumor size had decreased 
after treatment with siRNA (Oh et al., 2011) or 
shRNA (Ou et al., 2014) targeting BIRC7. 
Head and neck squamous cell 
carcinoma 
Yoon et al. (2017) demonstrated that BIRC7 is 
involved in chemoresistance in head and neck 
squamous cell carcinoma (HNSCC). This was 
evidenced in experiments using human HNSCC cell 
lines, where depletion of BIRC7 enhanced 
cytotoxicity of cisplatin, 5-FU, and docetaxel. 
Additionally, the authors detected elevated 
expression of cleaved caspases-3 and -7 and PARP1, 
when compared with control cells, after 
chemotherapy treatment, suggesting that reduction 
of BIRC7 levels is associated to sensitization to 
apoptosis (Yoon et al., 2017). 
Kidney cancer 
According to Xu et al. (2010), overexpression of 
BIRC7 was detected in 40.7% of the cases of renal 
cell carcinoma (RCC). Similarly, studies carried out 
by Zang et al. (2013) revealed BIRC7 was detected 
in 44% of cases of RCC. Furthermore, when 
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metastatic lymph nodes were detected, cases with 
overexpression of BIRC7 came up to 59% (Wagener 
et al., 2007).  
Clinical studies indicated that tissues from advanced 
stages of RCC have greater expression of BIRC7 
(Wang et al., 2016). Functional studies strongly 
suggested that BIRC7 is a bridge for apoptosis and 
autophagy. Silencing of BIRC7 induced apoptosis 
and autophagic cell death while also increasing 
sensitivity to cisplatin in RCC cells (Wang et al., 
2016). 
Laryngeal cancer 
Studies have reported that BIRC7 inhibits cell 
apoptosis via modulation of caspase 3, caspase 7 and 
PARP1 in human larynx and pharynx carcinoma 
cells. In laryngohypopharyngeal carcinoma 
(LHSCC), BIRC7 expression was predominantly 
identified in tumors (36.7%) when compared to the 
adjacent healthy mucosa. Additionally, induction of 
apoptosis by BIRC7 knockdown occurred through 
activation of caspases-3 and 7 and PARP1. Such data 
indicate that BIRC7 induces tumorigenic activities in 
LHSCC, such as resistance to apoptosis. Thus, 
BIRC7 silencing may be useful for therapeutic 
intervention against tumor progression in LHSCC 
(Kuang et al., 2017, Liu et al., 2016).  
In patients with nasopharyngeal carcinoma (NPC), 
high expression levels of BIRC7 occurred in 65.1% 
of cases, suggesting BIRC7 to be implicated in 
progression of such disease. Thus, this may be a 
useful prognostic biomarker for NPC (Kuang et al., 
2017, Liu et al., 2016). Nevertheless, observational 
studies have shown that the efficacy of radiotherapy 
is greater in patients who did not express BIRC7 
compared to those with BIRC7 overexpression, 
indicating that BIRC7 may be associated with a poor 
prognosis for NPC and LHSCC (Kuang et al., 2017, 
Liu et al., 2016). 
Leukemia 
Overexpression of BIRC7 was found in 
approximately 81% of patients with acute myeloid 
leukemia (AML), and a positive correlation between 
the expression of BIRC7 and high white blood cell 
counts was reported (Zareifar et al., 2018). In AML, 
genetic aberrations were found to activate BIRC7-
related signal transduction pathways, resulting in 
greater proliferation and/or survival of leukemia 
progenitor cells by affecting transcription factors or 
transcription coactivation components, resulting in 
differentiated blocking and/or aberrant acquisition of 
self-renewal properties by hematopoietic progenitor 
cells (Dohner et al., 2008; Hanahan et al., 2000; 
Zareifar et al., 2018).  
Additionally, levels of BIRC7 expression in acute 
lymphoblastic leukemia (ALL) were also shown to 
be elevated. Such feature may be attributed to the 
different mutations that occurred in the two types of 
leukemia that further lead to leukemogenesis 
(Ibrahim et al., 2014; Choi et al., 2019).  
Overexpression of BIRC7 protein in newly 
diagnosed children with acute leukemia suggested an 
important role for this protein in carcinogenesis and 
progression of such disease (Lv et al., 2015). Yang 
et al. (2010) also suggested that the expression of 
BIRC7α and BIRC7β may be associated with 
genesis and development of acute leukemia in 
childhood, and that this could be used as a molecular 
marker of childhood acute leukemia. In addition, 
BIRC7 can be used as a new target for leukemia 
treatment, as RNAi technology effectively inhibited 
expression of BIRC7 (Yang et al., 2010; Yan et al., 
2011; Ibrahim et al., 2014). 
Liver cancer 
BIRC7 mRNAs were significantly increased in 
samples from hepatocellular carcinoma patients 
compared to their normal hepatic tissues (Augello et 
al., 2009), hepatitis, and hepatic cirrhosis tissues 
(Guo et al., 2013).  
BIRC7 inhibition, by shRNA, promoted apoptosis in 
hepatocellular carcinoma cell line HepG2, which 
was even more evident with a combinatory strategy 
using the co-transfection with a shRNA targeting 
BIRC5 (Xu et al., 2014). Additionally, another study 
demonstrated that inhibition of BIRC7 using shRNA 
increased chemosensitivity of HepG2 cells (Liu et 
al., 2015).  
Similar results were obtained in other hepatocellular 
carcinoma cell line, SMMC-7721, using BIRC7 
siRNA. Inhibition of BIRC7 sensitized cells to pro-
apoptotic stimuli associated with caspase 3 
activation and, moreover, promoted cell growth 
inhibition specifically by mitotic arrest. In addition, 
BIRC7 depletion reduced the invasive capacity of 
hepatocellular carcinoma cells, demonstrating that 
BIRC7 is not only involved in resistance to 
apoptosis, but also in cell proliferation and 
invasiveness (Liu et al., 2010).  
BIRC7 not only provided resistance to 
hepatocellular carcinoma cells, but also significantly 
contributed to cell proliferation and invasion (Liu, 
2010). In addition, clinical studies showed that 
overexpression of BIRC7α isoform correlates with a 
high risk of relapse in liver cancer (Liu, 2007; Liu, 
2010).  
Inhibition of BIRC7 gene expression was associated 
with a strong increase in apoptotic response in the 
presence of pro-apoptotic agents, indicating that 
BIRC7 depletion led to sensitization to apoptotic 
stimuli (Mazumder, 2008; Liu, 2010). Moreover, 
negative regulation of BIRC7 expression induced 
cell cycle arrest at the G0/G1 phase, indicating that 
BIRC7 modulation may be a potential targeted 
approach for the treatment of liver cancer (Wang, 
2008; Liu, 2010) 
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Lung cancer 
High levels of BIRC7 were detected in 
approximately 61.5% of cases of non-small cell lung 
cancer (NSCLC). Conversely, BIRC7 
overexpression was associated with poor prognosis 
and lymph node metastasis (Crnkovic-Mertens et al., 
2006; Yuan et al., 2008).  
Functional studies showed that silencing of BIRC7 
increased the efficiency of chemotherapy or 
radiotherapy in pulmonary adenocarcinomas. In 
addition, this protein is portrayed as a potential 
predictive biomarker for the prognosis of lung 
adenocarcinoma besides a promising strategy for 
drug-resistant lung adenocarcinoma (Yang et al., 
2014; Wu et al., 2016; Liang et al., 2017). 
Lymphoma 
The expression of BIRC7 in non-Hodgkins 
lymphoma (NHL) was significantly higher than in 
lymph node samples in classical Hodgkins 
lymphomas (CHL). This difference in BIRC7 
expression was also observed when comparing two 
NHL subtypes - large B-cell lymphoma (DLBCL) 
and large cell anaplastic lymphoma for CHL - where 
a significantly higher expression of BIRC7 occurred 
in DLBCL (Tanhaei et al., 2014; Ziaei et al, 2015; 
Browne et al., 2003).  
BIRC7 plays a critical role in the pathogenesis of 
lymphomas and was detected in 40% of cases 
Hodgkin's lymphoma and 48% in cases of Burkitt's 
lymphoma, indicating that BIRC7 could be a 
potential marker and therapeutic target for these 
diseases (Abd-Elrahamn et al., 2009; Kalungi et al., 
2012). 
Melanoma 
BIRC7 is also named Melanoma-Inhibitor Apoptosis 
Protein (ML-IAP) due to the first paper that reported 
an elevated expression of this IAP in melanoma cell 
lines, when compared to that of some lymphomas, 
fetal kidney, fetal liver, testis and thymus. The study 
further demonstrated that BIRC7 mRNA was highly 
expressed in melanoma cell lines but not in normal 
human melanocytes. Moreover, such expression was 
consistent with a resistant phenotype to 
chemotherapeutic agents, also becoming the first 
work to demonstrate the importance of BIRC7 on 
chemoresistance (Vucic et al., 2000).  
BIRC7 showed low occurrence in nevi (15%), 
however an increased expression in melanoma (47.6 
- 70.7%), in which these levels came up to 95% in 
metastatic melanoma, suggesting this protein to be 
involved in melanoma progression (Hartman  Czyz, 
2013). In this scenario, high BIRC7 levels were 
associated with a poor prognosis in melanoma 
(Lazar et al., 2012). Still, silencing of BIRC7 
induced apoptosis, by activation of caspase 3, and 
cell cycle arrest at the G0/G1 phase, thus inhibiting 
proliferation of LiBr melanoma cells (Wang et al., 
2007).DISEASE 
Mesothelioma 
BIRC7 protein was expressed in 18% of malignant 
pleural mesothelioma (MPM) and was usually found 
in the nucleus of these cells. Only BIRC2 (IAP1) and 
BIRC7 proteins were expressed in the nucleus of 
MPM tumors (Gordon et al., 2007). 
Oral squamous cell carcinoma 
BIRC7 was increased in human oral squamous cell 
carcinoma (OSCC) tissues compared with the 
adjoining healthy mucosa. Additionally, BIRC7 
knockdown reduced cell invasion, migration, and 
proliferation in the human OSCC cells, while also 
promoting apoptosis, evidenced by activation of 
caspases (Lee et al., 2014). 
Ovarian cancer 
Elevated expression levels of BIRC7 isoforms were 
detected in human epithelial ovarian cancer (EOC) 
in comparison to benign ovarian neoplasms. 
Moreover, depletion of BIRC7 levels by shRNA 
result in profound pro-apoptotic and antiproliferative 
effects, and was associated with the activation of 
caspase signaling, increased apoptosis and recovered 
sensitivity to chemotherapy drugs (Liu et al., 2012). 
Osteosarcoma 
BIRC7 expression was upregulated in 58.7% of 
human osteosarcoma tissue, which, in turn, showed 
a significant correlation with microvascular density, 
suggesting that regulation of BIRC7 expression 
could further control the physiological repair of 
pathological angiogenesis in osteosarcomas (Li et al, 
2014; Guan, 2015)  
As BIRC7 has rarely been found in osteochondroma 
tissues, this feature may be indicative of a specificity 
of such protein to osteosarcomas. In invasive 
osteosarcomas metastatic tissues, BIRC7 was 
notoriously elevated, suggesting that the higher 
levels of this protein conferred anti-apoptotic effects 
and endurance of these tumor cells (Li et al, 2012). 
In this context, BIRC7 may serve as a promising 
therapeutic target for the treatment of 
osteosarcomas. Furthermore, expression of BIRC7 
was related to a poor prognosis of osteosarcoma and 
its detection may play an important role in evaluation 
of this type of cancer (Li et al, 2012; Li et al, 2014; 
Sun et al., 2018). 
Pancreas cancer 
BIRC7 was shown to be overexpressed in 25% of 
pancreatic cancer cases. Additionally, this protein 
displayed strong reactivity in tumor tissues by in situ 
hybridization studies. Such reactivity was not found 
in all ducts, indicating heterogeneity for BIRC7 
expression is not merely related to tumor type or 
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origin, but also in different areas of a same tumor 
(Lopes et al., 2007, Liu et al., 2011).  
In PANC-1 cells, pharmacological studies have 
shown oxymatrine-induced apoptosis to be related to 
downregulation of BIRC7 and upregulation of the 
BAX / BCL2 ratio (Lopes et al., 2007, Liu et al., 
2011). 
Prostate cancer 
Expression of BIRC7β was detected in 51.9% of 
cases of testicular germ cell tumor, whereas 28.2% 
of cases of such pathology expressed BIRC7α 
(Kempkensteffen et al., 2008).  
In prostate carcinoma tissues, BIRC7 overexpression 
was associated with high-grade clinical stages of the 
disease and metastasis. This protein plays an 
important role in initiation of prostate cancer and 
promotes cell proliferation by regulating the G1/S 
cell cycle transition. BIRC7 has been related with 
invasion of cancer cells in the surrounding prostate 
tissue by affecting NF-KB signaling pathway and 
expressions of FN1 and CXCR4, resulting in 
inhibition of PTK2 (FAK) and SRC, and of ITGA5 
and ITGB3 (integrins a5 and b3) (Ye et al, 2011; 
Chen et al., 2012) 
Retinocytoma 
BIRC7 was found to be upregulated in retinocytoma 
compared to the normal control group. Treatment 
with topotecan induced apoptosis through the 
inhibition of BIRC7 expression (Zhang et al., 2013). 
Urinary tract cancer 
BIRC7 expression was upregulated in urinary tract 
cancers - bladder transitional cell carcinoma (TCC) 
and bladder squamous cell carcinoma (SCC) -when 
paralleled with corresponding adjacent non-
neoplastic tissues. Such elevated expression was 
significantly associated with higher tumor grades 
and staging, suggesting BIRC7 contributes to the 
progression of bladder carcinoma (Gayyeda  
Tawfiekb, 2015). 
To be noted 
Pharmacological advances targeting BIRC7 in 
cancer:  
Treatment with siRNA targeting BIRC7 
significantly suppressed cancer cell growth and 
enhanced cytotoxicity of typical anticancer drugs 
such as 5-FU and oxaliplatin (L-OHP) in colorectal 
cancer, demonstrating such protein to be a relevant 
target in oncology (Oh et al., 2016). Similarly, a 
study using a protamine single-chain antibody fusion 
protein (anti-MM scFv-tP) to deliver BIRC7 siRNA 
to melanoma LiBr cells revealed suppression of cell 
proliferation and induction of apoptosis, both in vitro 
and in vivo (Wang et al., 2017).  
A synthetic oligonucleotide containing 
unmethylated CpG oligodeoxynucleotides (CpG-
ODN) was evaluated in combination with 5-FU in 
the hepatocellular carcinoma cell line HepG2 and 
verified that such treatment decreased cell viability, 
increased apoptosis and induced cell cycle arrest at 
the S phase when compared with CpG-ODN or 5-FU 
alone. Alongside, expression of mRNA for BIRC7 
decreased in cells treated with CpG-ODN alone or in 
combination with 5-FU, but increased in cells treated 
with 5-FU alone (Liang et al., 2013).  
Supplementation diets rich in n-3 polyunsaturated 
fatty acids (PUFAs) have been associated with a 
reduced risk for several types of cancer which, in 
turn, has been linked to their effect in reducing the 
levels of expression of IAP family members 
associated with chemotherapy resistance and cancer 
malignancy, such as BIRC7 and BIRC5 (Slagsvold 
et al., 2010).  
Funding:  Process numbers: 2017/09022-8, 
2018/06522-2 and 2015/17177-6, Fundação de 
Amparo à Pesquisa do Estado de São Paulo 
(FAPESP) and Coordenação de Aperfeiçoamento de 
Pessoal de Nível Superior (CAPES). 
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